<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        57-370-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        JALRA M 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METFORMIN HYDROCHLORIDE,VILDAGLIPTIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1000,50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        98.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS Pharma Stein AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS Pharma Stein AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 389]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Arabian Japanese Pharmaceutical Co. Ltd.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BD08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances of Jalra M, vildagliptin and metformin, belong to a<br />group of medicines called &ldquo;oral antidiabetics&rdquo;.<br />Jalra M is used to treat adult patients with type 2 diabetes. This type of<br />diabetes is also known as non-insulin-dependent diabetes mellitus. Jalra M<br />is used when diabetes cannot be controlled by diet and exercise alone and/<br />or with other medicines used to treat diabetes )insulin or sulphonylureas(.<br />Type 2 diabetes develops if the body does not make enough insulin or if the<br />insulin that the body makes does not work as well as it should. It can also<br />develop if the body produces too much glucagon.<br />Both insulin and glucagon are made in the pancreas. Insulin helps to lower<br />the level of sugar in the blood, especially after meals. Glucagon triggers the<br />liver to make sugar, causing the blood sugar level to rise.<br /><strong>How Jalra M works</strong><br />Both active substances, vildagliptin and metformin, help to control the<br />level of sugar in the blood. The substance vildagliptin works by making the<br />pancreas produce more insulin and less glucagon. The substance metformin<br />works by helping the body to make better use of insulin. This medicine has<br />been shown to reduce blood sugar, which may help to prevent complications<br />from your diabetes.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take Jalra M</strong><br />- if you are allergic to vildagliptin, metformin or any of the other ingredients<br />of this medicine )listed in section 6(. If you think you may be allergic to any<br />of these, talk to your doctor before taking Jalra M.<br />- if you have uncontrolled diabetes, with, for example, severe hyperglycaemia<br />)high blood glucose(, nausea, vomiting, diarrhoea, rapid weight loss, lactic<br />acidosis )see &ldquo;Risk of lactic acidosis&rdquo; below( or ketoacidosis. Ketoacidosis is a<br />condition in which substances called ketone bodies accumulate in the blood<br />and which can lead to diabetic pre-coma. Symptoms include stomach pain<br />fast and deep breathing, sleepiness or your breath developing an unusual<br />fruity smell.<br />- if you have recently had a heart attack or if you have heart failure or serious<br />problems with your blood circulation or difficulties in breathing which could<br />be a sign of heart problems.<br />- if you have severely reduced kidney function.<br />- if you have a severe infection or are seriously dehydrated )have lost a lot<br />of water from your body(.<br />- if you are going to have a contrast x-ray )a specific type of x-ray involving<br />an injectable dye(.<br />Please also see information about this in section &ldquo;Warnings and precautions&rdquo;<br />- if you have liver problems<br />- if you drink alcohol excessively )whether every day or only from time to<br />time(.<br />- if you are breast-feeding )see also &ldquo;Pregnancy and breast-feeding&rdquo;(.<br /><strong>b. Take special care with Jalra M</strong><br />Risk of lactic acidosis<br />Jalra M may cause a very rare, but very serious side effect called lactic<br />acidosis, particularly if your kidneys are not working properly. The risk of<br />developing &nbsp;lactic &nbsp;acidosis &nbsp;is &nbsp;also &nbsp;increased &nbsp;with &nbsp;uncontrolled &nbsp;diabetes<br />serious &nbsp;infections, &nbsp;prolonged &nbsp;fasting &nbsp;or &nbsp;alcohol &nbsp;intake, &nbsp;dehydration &nbsp;)see<br />further information below(, liver problems and any medical conditions in<br />which a part of the body has a reduced supply of oxygen )such as acute<br />severe &nbsp;heart &nbsp;disease(.<br />If any of the above apply to you, talk to your doctor for further instructions<br />Stop taking Jalra M for a short time if you have a condition that may be<br />associated with dehydration )significant loss of body fluids( such as severe<br />vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than<br />normal. Talk to your doctor for further instructions.<br />Stop taking Jalra M and contact a doctor or the nearest hospital immediately<br />if you experience some of the symptoms of lactic acidosis, as this condition<br />may lead to coma<br />Symptoms of lactic acidosis include:<br />- vomiting<br />- stomach ache )abdominal pain(<br />- muscle cramps<br />- a general feeling of not being well with severe tiredness<br />- difficulty in breathing<br />- reduced body temperature and heartbeat<br />Lactic acidosis is a medical emergency and must be treated in a hospital.<br />Jalra M is not a substitute for insulin. Therefore, you should not receive Jalra<br />M for the treatment of type 1 diabetes.<br />Talk to your doctor, pharmacist or nurse before taking Jalra M if you have or<br />have had a disease of the pancreas.<br />Talk to your doctor, pharmacist or nurse before taking Jalra M if you are<br />taking an anti-diabetic medicine known as a sulphonylurea. Your doctor may<br />want to reduce your dose of the sulphonylurea when you take it together<br />with Jalra M in order to avoid low blood glucose )hypoglycaemia(.<br />If you have previously taken vildagliptin but had to stop taking it because of<br />liver disease, you should not take this medicine<br />Diabetic skin lesions are a common complication of diabetes. You are advised<br />to follow the recommendations for skin and foot care that you are given by<br />your doctor or nurse. You are also advised to pay particular attention to new<br />onset of blisters or ulcers while taking Jalra M. Should these occur, you should<br />promptly consult your doctor.<br />If you need to have major surgery you must stop taking Jalra M during and for<br />some time after the procedure. Your doctor will decide when you must stop<br />and when to restart your treatment with Jalra M.<br />A test to determine your liver function will be performed before the start of<br />Jalra M treatment, at three-month intervals for the first year and periodically<br />thereafter. This is so that signs of increased liver enzymes can be detected<br />as early as possible<br />During treatment with Jalra M, your doctor will check your kidney function at<br />least once a year or more frequently if you are elderly and/or have worsening<br />renal function.<br />Your doctor will test your blood and urine for sugar regularly<br />Children and adolescents<br />The use of Jalra M in children and adolescents up to 18 years of age is not<br />recommended.<br /><strong>c. Taking other medicines herbal or dietary supplements</strong><br />If you need to have an injection of a contrast medium that contains iodine<br />into your bloodstream, for example in the context of an X-ray or scan, you<br />must stop taking Jalra M before or at the time of the injection. Your doctor<br />will decide when you must stop and when to restart your treatment with<br />Jalra M.<br />Tell your doctor if you are taking, have recently taken or might take any other<br />medicines. You may need more frequent blood glucose and kidney function<br />tests, or your doctor may need to adjust the dosage of Jalra M. It is especially<br />important to mention the following:<br />- glucocorticoids generally used to treat inflammation<br />- beta-2 agonists generally used to treat respiratory disorders<br />- other medicines used to treat diabetes<br />- medicines which increase urine production )diuretics(<br />- medicines used to treat pain and inflammation )NSAID and COX-2-inhibitors<br />such as ibuprofen and celecoxib(<br />- certain medicines for the treatment of high blood pressure )ACE inhibitors<br />and angiotensin II receptor antagonists(<br />- certain medicines affecting the thyroid<br />- certain medicines affecting the nervous system<br />- certain medicines used to treat angina )e.g. ranolazine(<br />- certain medicines used to treat HIV infection )e.g. dolutegravir(<br />- certain medicines used to treat a specific type of thyroid cancer )medullary<br />thyroid cancer( )e.g. vandetanib(<br />- certain medicines used to treat heartburn and peptic ulcers )e.g cimetidine(<br /><strong>d. Taking Jalra M with food and drink</strong><br />Avoid excessive alcohol intake while taking Jalra M since this may increase<br />the risk of lactic acidosis )please see section &ldquo;Warnings and precautions&rdquo;(<br /><strong>e. Pregnancy and breast-feeding</strong><br />- If you are pregnant, think you may be pregnant or are planning to have a<br />baby, ask your doctor for advice before taking this medicine. Your doctor will<br />discuss with you the potential risk of taking Jalra M during pregnancy.<br />- Do not use Jalra M if you are pregnant or breast-feeding )see also &ldquo;Do not<br />take Jalra M&rdquo;(.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br /><strong>f. Driving and using machines</strong><br />If you feel dizzy while taking Jalra M, do not drive or use any tools or machines.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The amount of Jalra M that people have to take varies depending on their<br />condition. Your doctor will tell you exactly the dose of Jalra M to take.<br />Always take this medicine exactly as your doctor has told you. Check with<br />your doctor or pharmacist if you are not sure.<br />The recommended dose is one film-coated tablet of either 50 mg/850 mg or<br />50 mg/1000 mg taken twice a day<br />If you have reduced kidney function, your doctor may prescribe a lower dose.<br />Also if you are taking an anti-diabetic medicine known as a sulphonylurea<br />your doctor may prescribe a lower dose.<br />Your doctor may prescribe this medicine alone or with certain other medicines<br />that lower the level of sugar in your blood.<br /><strong>When and how to take Jalra M</strong><br />- Swallow the tablets whole with a glass of water,<br />- Take one tablet in the morning and the other in the evening with or just<br />after food. Taking the tablet just after food will lower the risk of an upset<br />stomach.<br />Continue to follow any advice about diet that your doctor has given you. In<br />particular, if you are following a diabetic weight control diet, continue with<br />this while you are taking Jalra M.<br /><strong>a. If you take more Jalra M than you should</strong><br />If you take too many Jalra M tablets, or if someone else takes your tablets,<br />talk to a doctor or pharmacist immediately. Medical attention may be<br />necessary. If you have to go to a doctor or hospital, take the pack and this<br />leaflet with you.<br /><strong>b. If you forget to take Jalra M</strong><br />If you forget to take a tablet, take it with your next meal unless you are due<br />to take one then anyway. Do not take a double dose )two tablets at once( to<br />make up for a forgotten tablet.<br /><strong>c. If you stop taking Jalra M</strong><br />Continue to take this medicine as long as your doctor prescribes it so that it<br />can continue to control your blood sugar. Do not stop taking Jalra M unless<br />your doctor tells you to. If you have any questions about how long to take<br />this medicine, talk to your doctor.<br />If you have any further questions on the use of this medicine, ask your<br />doctor, pharmacist or nurse.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />You should<strong> stop taking Jalra M and see your doctor immediately </strong>if you<br />experience the following side effects:<br /><strong>&bull; Lactic acidosis</strong> )very rare: may affect up to 1 in 10 000 people(: Jalra M<br />may cause a very rare, but very serious side effect called lactic acidosis )see<br />section &ldquo;Warnings and precautions&rdquo;(. If this happens you must <strong>stop taking<br />Jalra M and contact a doctor or the nearest hospital immediately</strong>, as<br />lactic acidosis may lead to coma.<br /><strong>&bull; Angioedema</strong> )rare: may affect up to 1 in 1 000 people(: Symptoms include<br />swollen face, tongue or throat, difficulty swallowing, difficulty breathing,<br />sudden onset of rash or hives, which may indicate a reaction called<br />&ldquo;angioedema&rdquo;.<br /><strong>&bull; Liver disease </strong>)hepatitis( )uncommon: may affect up to 1 in 100 people(:<br />Symptoms include yellow skin and eyes, nausea, loss of appetite or darkcoloured urine, which may indicate liver disease )hepatitis(.<br /><strong>&bull; Inflammation of the pancreas )</strong>pancreatitis( )uncommon: may affect up<br />to 1 in 100 people(:<br />Symptoms include severe and persistent pain in the abdomen )stomach area(,<br />which might reach through to your back, as well as nausea and vomiting.<br /><strong>Other side effects</strong><br />Some patients have experienced the following side effects while taking Jalra<br />M:<br />&bull; Common )may affect up to 1 in 10 people(: sore throat, runny nose, fever,<br />itchy rash, excessive sweating, joint pain, dizziness, headache, trembling<br />that cannot be controlled, constipation, nausea )feeling sick(, vomiting,<br />diarrhoea, flatulence, heartburn, pain in and around the stomach )abdominal<br />pain(.<br />&bull; Uncommon )may affect up to 1 in 100 people(: tiredness, weakness,<br />metallic taste, low blood glucose, loss of appetite, swollen hands, ankles or<br />feet )oedema(, chills, inflammation of the pancreas, muscle pain.<br />&bull; Very rare )may affect up to 1 in 10 000 people(: signs of a high level of<br />lactic acid in the blood )known as lactic acidosis( such as drowsiness or<br />dizziness, severe nausea or vomiting, abdominal pain, irregular heart beat<br />or deep, rapid breathing; redness of the skin, itching; decreased vitamin B12<br />levels )paleness, tiredness, mental symptoms such as confusion or memory<br />disturbances(.<br />Since this product has been marketed, the following side effects have also<br />been reported:<br />&bull; Frequency not known )cannot be estimated from the available data(:<br />localised peeling of skin or blisters, blood vessel inflammation )vasculitis(<br />which may result in skin rash or pointed, flat, red, round spots under the<br />skin&#39;s surface or bruising.<br /><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This<br />includes any possible side effects not listed in this leaflet. By reporting<br />side effects you can help provide more information on the safety of this<br />medicine. You can also report side effects directly.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep this medicine out of the sight and reach of children.<br />- Do not use this medicine after the expiry date which is stated on the blister<br />and carton after &ldquo;EXP&rdquo;.<br />The expiry date refers to the last day of that month.<br />- Do not store above 30&deg;C.<br />- Store in the original package )blister( in order to protect from moisture.<br />- Do not throw away any medicines via wastewater or household waste. Ask<br />your pharmacist how to throw away medicines you no longer use. These<br />measures will help protect the environment.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>- The active substances</strong> are vildagliptin and metformin hydrochloride.<br />- Each Jalra M 50 mg/850 mg film-coated tablet contains 50 mg vildagliptin<br />and 850 mg metformin hydrochloride )corresponding to 660 mg of<br />metformin(.<br />- Each Jalra M 50 mg/1000 mg film-coated tablet contains 50 mg vildagliptin<br />and 1000 mg metformin hydrochloride )corresponding to 780 mg of<br />metformin(.<br /><strong>- The other ingredients</strong> are: Hydroxypropylcellulose, magnesium stearate,<br />hypromellose, titanium dioxide )E 171(, yellow iron oxide )E 172(, macrogol<br />4000 and talc.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Jalra M is available in pack containing 60 film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SAJA Pharmaceuticals<br />Saudi Arabian Japanese pharmaceutical company limited<br />Jeddah &ndash; Saudi Arabia<br />Under License from Novartis Pharma AG, Switzerland<br />&nbsp;</p><p><strong>-To report any side effect (s)</strong><br /><strong>&bull; Saudi Arabia</strong><br />- The National Pharmacovigilance Centre )NPC(:<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa<br /><strong>&bull; Other GCC states /other countries</strong><br />-Please contact the relevant competent authority.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تنتمي المواد الفعالة فیلداجلیبتن ومیتفورمین الموجودة بدواء جالرا إم إلى فئة من الأدوية تسمى &quot;الأدوية المضادة لمرض السكري عن طريق الفم.&quot;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم دواء جالرا إم لعلاج المرضى البالغين الذين يعانون من مرض السكري النوع الثاني. يعرف أيضًا هذا النوع من السكري بمرض السكري غير المُعتمِد على الأنسولين. يستخدم جالرا إم عندما لا يمكن السيطرة على مرض السكري عن طريق النظام الغذائي وممارسة الرياضة وحدها و / أو مع الأدوية الأخرى المستخدمة لعلاج مرض السكري (الأنسولين أو السلفونیل یوریا) .&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتم الإصابة بمرض السكري من النوع الثاني إذا لم ينتج الجسم كمية كافية من الأنسولين أو إذا كان الأنسولين الذي ينتجه الجسم لا يعمل كما يجب. من الممكن الإصابة به أيضًا إذا كان الجسم ينتج كمية كبيرة من الجلوكاجون.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم تصنيع كل من الأنسولين والجلوكاجون في البنكرياس. يساعد الأنسولين على خفض مستوى السكر في الدم، خاصةً بعد تناول الوجبات. يحفز الجلوكاجون الكبد لإنتاج السكر، مما يؤدي إلى ارتفاع مستوى السكر بالدم. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يعمل دواء جالرا إم؟&nbsp;</strong></p><p dir="RTL">تسُاعد كلتا المادتين الفعالتين، فیلداجلیبتن ومیتفورمین، على التَّحكم بمستوى السكر في الدم. تعمل مادة فیلداجلیبتن عن طريق جعل البنكرياس ينتج المزيد من الأنسولين والقليل من الجلوكاجون. تعمل مادة المیتفورمین عن طريق مساعدة الجسم على استخدام الأنسولين بشكل أفضل. وقد تبين أن هذا الدواء يخفض سكر الدم، مما قد يساعد على منع حدوث مضاعفات ناتجة عن مرض السكرِي لديك. &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ . موانع استعمال دواء جالرا إم:</strong></p><p dir="RTL">- إذا كنت تعاني من حساسية تجاه فیلداجلیبتن أو میتفورمین أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: ٦). إذا كنت تعتقد أنك تعاني من حساسية تجاه أيّ من هذه المواد، فتحدَّث إلى طبيبك قبل تناول دواء جالرا إم.</p><p dir="RTL">- إذا كنت تعاني من مرض السُّكَّرِي غير المنضبط، مع، على سبيل المثال: فرط سكر الدَّم الشديد (ارتفاع جلوكوز الدَّم)، أو غثيان، أو قيء، أو إسهال، أو فقدان الوزن السريع، أو حموضة الدم بسبب الأحماض اللبنية (انظر قسم: &quot;خطر حموضة الدم بسبب الأحماض اللبنية &quot; أدناه) أو الحُماض الكیتوني. الحُماض الكیتوني عبارة عن حالة تتراكم فيها مواد تسُمى الأجسام الكیتونیة في الدَّم والتي من الممكن أن تؤُدي إلى مقدمات الغيبوبة السكرية. تشمل أعراض هذه الحالة:</p><p dir="RTL">ألم بالمعدة، تنفس سريع وعميق، نعاس أو ظهور رائحة فاكهة غير معتادة بالتنَّفس لديك.</p><p dir="RTL">- إذا كنت قد أصبت مؤخرًا بنوبة قلبية أو إذا كنت تُعاني من قصور القلب أو مشاكل خطيرة بالدورة الدموية لديك أو صعوبات بالتنفس والتي من الممكن أن تكون علامة على وجود مشاكل بالقلب.</p><p dir="RTL">- إذا كنت تعاني من قصور شديد في وظائف الكلى.</p><p dir="RTL">- إذا كنت مصاباً بعدوى شديدة أو أصبت بجفاف بشكل خطير (فقدت كمية كبيرة من الماء الموجود بجسمك).</p><p dir="RTL">- إذا كنت بصدد إجراء أشعة سینیة متباينة (نوع معين من الأشعة السینیة تتضمن إعطاء صبغة عن طريق الحقن). يرجى أيضًا الاطلاع على معلومات حول هذا الموضوع في قسم: &quot;الاحتياطات عند استعمال دواء جالرا إم&quot;.</p><p dir="RTL">- إذا كنت تعاني من مشاكل بالكبد.</p><p dir="RTL">- إذا كنت تتناول الكحوليات بشكل مفرط (سواء كان ذلك كل يوم أو من وقت لآخر).</p><p dir="RTL">- إذا كنتِ مرضعاً (انظري أيضًا قسم: &quot;الحمل والرضاعة&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب. الاحتياطات عند استعمال دواء جالرا إم:</strong></p><p dir="RTL">خطر حموضة الدم بسبب الأحماض اللبنية</p><p dir="RTL">قد يسبب دواء جالرا إم أثرا جانبيا نادرا جدا إلا أنه خطير جدا عرف بحموضة الدم بسبب الأحماض اللبنية، خاصة إذا لم تكن الكلى لديك تعمل بشكل جيد. يزداد أيضا خطر الإصابة بحموضة الدم بسبب الأحماض اللبنية مع مرض السكري غير المنضبط، العدوى الخطيرة، الصيام لفترات طويلة أو تناول الكحوليات، الجفاف (انظر قسم: &quot;معلومات إضافية&quot; أدناه، مشاكل الكبد وأي حالات طبية ينخفض فيها مخزون الأكسجين في أي جزء من الجسم (مثل مرض قلبي شديد وحاد).</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك، فتحدث إلى طبيبك للحصول على مزيد من التعليمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توقف عن تناول دواء جالرا إم لفترة قصيرة من الوقت إذا كنت مصاباً بحالة قد تكون مصحوبة بالجفاف (فقدان كبير لسوائل الجسم) مثل: القيء الشديد، أو الإسهال، أو الحمى، أو التعَّرض للحرارة، أو إذا كنت تشرب السوائل بشكل أقل من المعتاد. تحدَّث إلى طبيبك؛ للحصول على مزيد من التعليمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توقف عن تناول دواء جالرا إم واتصل بالطبيب أو أقرب مستشفى فورًا إذا تعرضت للإصابة ببعض أعراض حموضة الدم بسبب الأحماض اللبنية؛ إذ قد تُؤدي هذه الحالة إلى حدوث الغيبوبة.</p><p dir="RTL">تشمل أعراض حموضة الدم بسبب الأحماض اللبنية ما يلي:</p><p dir="RTL">- قيئ.</p><p dir="RTL">- ألم بالمعدة (ألم بالبطن).</p><p dir="RTL">- تقلصات عضلية.</p><p dir="RTL">- شعورًا عاما بأنك لست على ما يرام مع تعب شديد. &nbsp;</p><p dir="RTL">- صعوبة في التنَّفس.</p><p dir="RTL">- انخفاض درجة حرارة الجسم ومعدل ضربات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حموضة الدم بسبب الأحماض اللبنية هي حالة طبية طارئة ويجب علاجها في المستشفى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">دواء جالرا إم ليس بديلًا عن الأنسولين. لذلك، يجب عليك عدم تلقي دواء جالرا إم لعلاج مرض السكري من النوع الأول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك أو الممرض قبل تناوُل دواء جالرا إم إذا كنت تعاني أو قد عانيت من مرض بالبنكرياس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك أو الممرض قبل تناوُل دواء جالرا إم إذا كنت تتناول دواء مضادا لمرض السُّكَّرِي يعرف باسم سلفونیل یوریا. قد يريد طبيبك خفض جرعتك من سلفونیل یوریا عندما تتناولها بالتزامن مع دواء جالرا إم ؛ لتجنب جلوكوز الدَّم المنخفض (نقص سكر الدَّم) .</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت قد تناولت فیلداجلیبتن سابقًا ولكن توجب عليك التَّوقف عن تناوله بسبب مرض بالكبد، فيجب عليك عدم تناول هذا الدَّواء .</p><p dir="RTL">&nbsp;</p><p dir="RTL">إصابات الجلد السكرية هي أحد مضاعفات مرض السُّكَّرِي الشائعة. ينصح باتباع توصيات العناية بالجلد والقدمين التي أعطاك إياها طبيبك أو الممرض. ينصح أيضًا بتولي اهتمام خاص لأي ظهور جديد للبثور أو القرح أثناء تناول دواء جالرا إم. إذا حدث ذلك، يجب عليك استشارة طبيبك فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت بحاجة إلى إجراء جراحة كبرى فيجب عليك التوَّقف عن تناول دواء جالرا إم أثناء الجراحة ولبعض الوقت بعد إجرائها. سيقرر طبيبك متى يجب عليك إيقاف علاجك بدواء جالرا إم ومتى يتم استئنافه.</p><p dir="RTL">سيتم إجراء اختبار؛ لتحديد وظائف الكبد قبل بدء العلاج بدواء جالرا إم، على فواصل زمنية كل ثلاثة أشهر في العام الأول وبعد ذلك بصورة دورية. وذلك للتمَّكن من اكتشاف علامات ارتفاع مستوى إنزیمات الكبد في وقت مبكر قدر الإمكان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء العلاج بدواء جالرا إم، سيتحقق طبيبك من وظائف الكلى لديك على الأقل مرة واحدة في السنة أو بشكل أكثر تكرارًا إذا كنت من كبار السن و/ أو كان لديك تدهور في وظائف الكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقوم طبيبك بإجراء اختبار للدَّم والبول لديك لمراقبة السكر بانتظام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأطفال والمراهقون</p><p dir="RTL">لا يوصى باستخدام دواء جالرا إم في الأطفال والمراهقين حتى عمر ۱۸ عاما</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج التداخلات الدوائية من أخذ دواء جالرا إم مع أدوية أخرى أو أعشاب أو مكملات غذائية:</strong></p><p dir="RTL">إذا كنت بحاجة إلى حقن وسط تبايني الذي يحتوي على اليود داخل مجرى الدَّم لديك، على سبيل المثال: في سياق إجراء الأشعة السینیة أو الفحص، فيجب عليك التوَّقف عن تناول دواء جالرا إم قبل أو في وقت الحقن. سيقرر طبيبك متى يجب عليك إيقاف علاجك بدواء جالرا إم ومتى يتم استئنافه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى إبلاغ طبيبك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أية أدوية أخرى. قد تكون بحاجة إلى إجراء اختبارات جلوكوز الدَّم ووظائف الكلى بشكل أكثر تكرارًا، أو قد يكون طبيبك بحاجة إلى تعديل جرعة دواء جالرا إم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم معرفة التالي:</p><p dir="RTL">- الجلوكوكورتیكویدات بشكل عام لعلاج الالتهاب</p><p dir="RTL">- ناهضات بیتا - ۲ عمومًا لعلاج اضطرابات الجهاز التنَّفسي</p><p dir="RTL">- الأدوية الأخرى لعلاج مرض السُّكَّرِي</p><p dir="RTL">- الأدوية التي تزيد من إنتاج البول (مُدِرات البول)</p><p dir="RTL">- الأدوية التي تستخدم لعلاج الألم والالتهاب (مضادات الالتهاب غير الستیرویدیة ومثبطات الأكسدة الحلقية-۲، مثل إیبوبروفین وسیلیكوكسیب).</p><p dir="RTL">- بعض الأدوية لعلاج ارتفاع ضغط الدَّم (مُثبطات إنزیم تحويل الأنجیوتنسین ومناهضات مستقبلات أنجیوتنسین-۲).</p><p dir="RTL">- بعض الأدوية التي تؤُثر على الغدة الدرقية.</p><p dir="RTL">- بعض الأدوية التي تؤُثر على الجهاز العصبي.</p><p dir="RTL">- بعض الأدوية المستخدمة لعلاج الذبحة الصدرية (مثل رانولازین).</p><p dir="RTL">- بعض الأدوية المستخدمة لعلاج عدوى فيروس نقص المناعة البشرية (مثل دولوتغرافیر)</p><p dir="RTL">- بعض الأدوية المستخدمة لعلاج نوع معين من سرطان الغدة الدرقية (سرطان الغدة الدرقية النخاعي) (مثل فاندیتانیب)</p><p dir="RTL">- بعض الأدوية المستخدمة لعلاج حرقة المعدة والقرحة الهضمية (مثل سیمیتیدین).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>د. تناول دواء جالرا إم مع الطعام والشراب</strong></p><p dir="RTL">تناوُل دواء جالرا إم مع الكحوليات</p><p dir="RTL">تجنب تناول الكحوليات بإفراط أثناء تناول دواء جالرا إم؛ إذ قد يزيد هذا من خطر الإصابة بحموضة الدم بسبب الأحماض اللبنية (يرجى الرجوع إلى قسم: &quot;تحذيرات واحتياطات&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ . الحمل والرضاعة</strong></p><p dir="RTL">- إذا كنتِ حاملًا، أو تعتقدين أنكِ حامل أو تخططين للحمل، فاستشيري طبيبك قبل تناول هذا الدَّواء. سيناقش معكِ طبيبك المخاطر المحتملة لتناول دواء جالرا إم أثناء الحمل.</p><p dir="RTL">- لا تستخدمي دواء جالرا إم إذا كنتِ حاملًا أو مرضعًا (يرجى الرجوع إلى قسم: &quot;لا تتناول دواء جالرا إم&quot;).</p><p dir="RTL">استشيري طبيبك أو الصيدلي الخاص بكِ قبل تناول أي دواء .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و. تأثير دواء جالرا إم على القيادة واستخدام الآلات</strong></p><p dir="RTL">إذا شعرت بدوخة أثناء تناول دواء جالرا إم، فلا تمارس القيادة أو تستخدم أية أدوات أو آلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تختلف كمية دواء جالرا إم التي يجب على الأشخاص تناولها اعتمادًا على حالتهم. سيخبرك طبيبك بالضبط بالجرعة التي يجب عليك تناولها من دواء جالرا إم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناوَل دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية التناول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها هي قرص مغلف واحد بحجم إما ٥۰ ملج/ ۸٥۰ ملج أو ٥۰ ملج/ ۱۰۰۰ ملج يتم تناولها مرتين يوميا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من قصور بوظائف الكُلى، فقد يصف لك طبيبك جرعة أقل. أيضًا إذا كنت تتناول دواء مضادا لمرض السُّكَّرِي يعرف باسم سلفونیل یوریا، قد يصف لك طبيبك جرعة أقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يصف لك طبيبك هذا الدَّواء وحده أو مع بعض الأدوية الأخرى التي تقلل مستويات السكر لديك بالدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متى وكيف تتناول دواء جالرا إم؟</strong></p><p dir="RTL">- ابتلع الأقراص كاملة مع كوب من الماء.</p><p dir="RTL">- تناول قرصًا واحدًا في الصباح والآخر في المساء مع الطعام أو بعده مباشرة. سيحد تناول القرص بعد الطعام مباشرة من خطر الإصابة بتهيج المعدة.</p><p dir="RTL">استمر في اتباع أي مشورة أعطاها لك طبيبك حول النظام الغذائي. وعلى وجه الخصوص، إذا كنت تتبع نظاما غذائيا للتحكم في الوزن خاصًا بمرض السكري، فاستمر على ذلك أثناء تناول دواء جالرا إم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ . الجرعة الزائدة من دواء جالرا إم</strong></p><p dir="RTL">إذا تناولت الكثير من أقراص دواء جالرا إم، أو إذا تناول شخص آخر الأقراص الخاصة بك؛ فتحدَّث إلى الطبيب أو الصيدلي فورًا. قد تكون هناك ضرورة للعناية الطبية. إذا كان عليك الذهاب إلى الطبيب أو المستشفى، فاصطحب معك العبوة وهذه النشَّرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب. نسيان تناول جرعة من دواء جالرا إم</strong></p><p dir="RTL">إذا أغفلت تناول أحد الأقراص، فتناوله مع وجبتك التالية ما لم تكن بصدد تناول قرص آخر على أي حال. لا تتناول جرعة مضاعفة (قرصين في وقت واحد) لتعويض قرص أغفلته.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. التوقف عن تناول دواء جالرا إم</strong></p><p dir="RTL">استمر في تناوُل هذا الدَّواء للمدة التي يصفها لك طبيبك حتى تتمكن من الاستمرار في السيطرة على سكر الدَّم لديك. لا تتوقف عن تناوُل دواء جالرا إم ما لم يخبرك طبيبك بذلك. إذا كان لديك أي أسئلة حول مدة تناولك لهذا الدَّواء، فتحدَّث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك <strong>التوَّقف عن تناول دواء جالرا إم ورؤية الطبيب فورًا </strong>إذا تعرضت للآثار الجانبية التالية:</p><p dir="RTL"><strong>- حموضة الدم بسبب الأحماض اللبنية </strong>(نادر جدا: قد يؤثر في ما يصل إلى شخص واحد من بين كل١٠٠٠٠&rlm;):</p><p dir="RTL">قد يسبب دواء جالرا إم أثرا جانبيا نادرا جدا إلا أنه خطير جدا يعرف بحموضة الدم بسبب الأحماض اللبنية (انظر قسم: &quot;الاحتياطات عند استعمال دواء جالرا إم&quot;)&rlm; .إذا حدث ذلك، يجب عليك<strong> التوقف عن تناول دواء جالرا إم والاتصال بالطبيب أو أقرب مستشفى فورًا</strong>؛ إذ قد تؤدي الإصابة بحموضة الدم بسبب الأحماض اللبنية إلى حدوث الغيبوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>- وذمة وعائية </strong>(نادرة: قد تؤثر فيما يصل إلى شخص واحد من بين كل &lrm;١٠٠٠&rlm; شخص): تشمل الأعراض تورم الوجه أو اللسان أو الحلق، صعوبة البلع، صعوبة التنفس، ظهور مفاجئ للطفح الجلدي أو الشرى (أرتكاريا)، مما قد يشير إلى حدوث تفاعل يسمى: &quot;وذمة وعائية&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>- مرض بالكبد </strong>(التهاب الكبد الوبائي (نادر): تشمل الأعراض اصفرار الجلد والعينين، الغثيان، فقدان الشهية، أو بول داكن اللون مما قد يشير إلى وجود مرض بالكبد (التهاب الكبد الوبائي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>- التهاب البنكرياس</strong> (معدل التكرار غير معروف): تشمل الأعراض ألمًا شديدًا ومستمراً بالبطن (منطقة المعدة)، والذي قد يصل إلى ظهرك، وكذلك الغثيان والقيء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية أخرى:</strong></p><p dir="RTL">قد عانى بعض المرضى من الآثار الجانبية التالية أثناء تناولهم لدواء جالرا إم:</p><p dir="RTL">- شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ۱۰ أشخاص): التهاب الحلق، سيلان الأنف، حُمّى؛ طفح جلدي مصحوب بحكة، التعرق المفرط، ألم بالمفاصل، دوخة، صداع، ارتجاف لا يمكن التحكم به، إمساك، غثيان (شعور بالإعياء)، غثيان، إسهال، انتفاخ، حرقة في المعدة، ألم في المعدة وحولها (ألم بالبطن).</p><p dir="RTL">- غير شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ۱۰۰ شخص): تعب و ضعف، طعم معدني، انخفاض مستوى الجلوكوز بالدمَّ فقدان الشهية، تورم باليدين أو الكاحل أو القدم (وذمة)، قشعريرة، التهاب البنكرياس، ألم عضلي.</p><p dir="RTL">- نادرة جدا (قد تُؤثر فيما يصل إلى شخص واحد من بين كل &lrm;١٠٠٠٠&rlm; شخص): علامات ارتفاع مستوى حمض اللاكتيك في الدم (ما يعرف باسم حموضة الدم بسبب الأحماض اللبنية ) مثل: النعاس أو الدوخة، الغثيان أو القيء الشديد، ألم في البطن، عدم انتظام معدل ضربات القلب، أو التنفس العميق والسريع، احمرار الجلد، حكة، انخفاض مستويات فيتامين &quot;ب&rlm; &lrm;١٢&quot;&rlm; (شحوب، تعب، أعراض نفسية مثل ارتباك/ التباس أو اضطرابات الذاكرة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">منذ أن تم تسويق المنتج؛ تم أيضًا الإبلاغ عن الآثار الجانبية التالية:</p><p dir="RTL">- معدل التكرار غير معروف (لا يمكن تقديره من واقع البيانات المتاحة): تقشر موضعي بالجلد أو بثور، التهاب الأوعية الدموية (التهاب الأوعية الدموية) الذي قد يؤدي إلى طفح جلدي أو بقع مدببة، مسطحة، حمراء، دائرية تحت سطح الجلد أو كدمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أصُبت بأية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي أو الممرض. ويشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النشَّرة. من خلال إبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء. يمكنك أيضًا أن تبلغ عن الآثار الجانبية بشكل مباشر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدَّواء بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">- لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على الشريط والعبوة الكرتونية بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">- لا تقم بالتخزين في درجة حرارة تتعدى ۳۰ &deg;درجة مئوية.</p><p dir="RTL">- يجب حفظ الدَّواء داخل العبوة الأصلية (الشريط) للحماية من الرطوبة.</p><p dir="RTL">- لا ينبغي رمي الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>- المواد الفعالة </strong>هي فیلداجلیبتن وھیدروكلورید المیتفورمین.</p><p dir="RTL">- يحتوي كل قرص مغلف من دواء جالرا إم ٥۰ ملج/ ۸٥۰ ملج على ٥۰ ملج فیلداجلیبتن و ۸٥۰ ملج ھیدروكلورید المیتفورمین (ما يعادل ٦٦۰ ملج من میتفورمین).</p><p dir="RTL">- يحتوي كل قرص مغلف من دواء جالرا إم ٥۰ ملج/ ۱۰۰۰ ملج على ٥۰ ملج فیلداجلیبتن و ۱۰۰۰ ملج ھیدروكلورید المیتفورمین (ما يعادل ۷۸۰ ملج من میتفورمین).</p><p dir="RTL"><strong>- المكونات الأخرى</strong> هي: ھیدروكسي بروبيل السلیلوز، ستیرات الماغنسیوم، ھیبرومیلوز، ثاني أكسيد التيتانيوم (E171)، أكسيد الحديد الأصفر (E172) ماكروجول ٤۰۰۰ وتَلك.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوافر دواء جالرا إم في عبوة تحتوي على ٦۰ قرصًا مغلفاً .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ساجا الصيدلانية</p><p dir="RTL">الشركة العربية السعودية اليابانية للمنتجات الصيدلانية المحدودة</p><p dir="RTL">جدة &ndash; المملكة العربية السعودية</p><p dir="RTL">بترخيص من شركة نوفارتس فارما آيه جى، سويسرا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أية آثار جانبية</strong></p><p dir="RTL"><strong>&bull; المملكة العربية السعودية</strong></p><p dir="RTL">- المركز الوطني للتيقظ والسلامة الدوائية&nbsp;</p><p dir="RTL">- مركز اتصالات الهيئة العامة للغذاء والدواء السعودية : 19999</p><p dir="RTL">- البريد الإلكتروني:&nbsp;npc.drug@sfda.gov.sa</p><p dir="RTL">- الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&bull; دول الخليج الأخرى/ الدول الأخرى</strong></p><p dir="RTL">- الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس/ ٢٠٢٤
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                JALRA M 50 mg/850 mg film-coated tablets
 JALRA M 50 mg/1000 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                JALRA M 50 mg/850 mg film-coated tablets


Each film-coated tablet contains 50 mg of vildagliptin and 850 mg of metformin hydrochloride (corresponding to 660 mg of metformin).


JALRA M 50 mg/1000 mg film-coated tablets


Each film-coated tablet contains 50 mg of vildagliptin and 1000 mg of metformin hydrochloride (corresponding to 780 mg of metformin).


For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.


JALRA M 50 mg/850 mg film-coated tablets


Yellow, ovaloid film-coated tablet with bevelled edge, imprinted with “NVR” on one side and “SEH” on the other side.
 
JALRA M 50 mg/1000 mg film-coated tablets


Dark yellow, ovaloid film-coated tablet with bevelled edge, imprinted with “NVR” on one side and “FLO” on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>JALRA M is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients who are inadequately controlled with metformin hydrochloride alone.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Adults with normal renal function (GFR &ge; 90 ml/min)</u></em></p><p>The dose of antihyperglycaemic therapy with JALRA M should be individualised on the basis of the patient&rsquo;s current regimen, effectiveness and tolerability while not exceeding the maximum recommended daily dose of 100 mg vildagliptin. JALRA M may be initiated at either the 50 mg/850 mg or</p><p>50 mg/1000 mg tablet strength twice daily, one tablet in the morning and the other in the evening.</p><p>&nbsp;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients inadequately controlled at their maximal tolerated dose of metformin monotherapy:</p><p>The starting dose of JALRA M should provide vildagliptin as 50 mg twice daily (100 mg total daily dose) plus the dose of metformin already being taken.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients switching from co-administration of vildagliptin and metformin as separate tablets: JALRA M should be initiated at the dose of vildagliptin and metformin already being taken.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients inadequately controlled on dual combination with metformin and a sulphonylurea:</p><p>The doses of JALRA M should provide vildagliptin as 50 mg twice daily (100 mg total daily dose) and a dose of metformin similar to the dose already being taken. When JALRA M is used in combination witha sulphonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia.</p><p>&nbsp;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients inadequately controlled on dual combination therapy with insulin and the maximal tolerated dose of metformin:</p><p>The dose of JALRA M should provide vildagliptin dosed as 50 mg twice daily (100 mg total daily dose) and a dose of metformin similar to the dose already being taken.</p><p>&nbsp;</p><p>&nbsp;</p><p>The safety and efficacy of vildagliptin and metformin as triple oral therapy in combination with a thiazolidinedione have not been established.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Special populations</u></em><em> </em><em>Elderly (&ge; 65 years)</em></p><p>As metformin is excreted via the kidney, and elderly patients have a tendency to decreased renal function, elderly patients taking JALRA M should have their renal function monitored regularly (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p>&nbsp;</p><p>Renal impairment</p><p>A GFR should be assessed before initiation of treatment with metformin-containing products and at least annually thereafter. In patients at increased risk of further progression of renal impairment and in the elderly, renal function should be assessed more frequently, e.g. every 3-6 months.</p><p>&nbsp;</p><p>&nbsp;</p><p>The maximum daily dose of metformin should preferably be divided into 2-3 daily doses. Factors that may increase the risk of lactic acidosis (see section 4.4) should be reviewed before considering initiation of metformin in patients with GFR&lt;60 ml/min.</p><p>&nbsp;</p><p>&nbsp;</p><p>If no adequate strength of JALRA M is available, individual monocomponents should be used instead ofthe fixed dose combination.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>GFR ml/min</p></td><td style="vertical-align:top"><p>Metformin</p></td><td style="vertical-align:top"><p>Vildagliptin</p></td></tr><tr><td style="vertical-align:top"><p>60-89</p></td><td style="vertical-align:top"><p>Maximum daily dose is 3000 mg.</p><p>Dose reduction may be considered in relation to declining renal function.</p></td><td style="vertical-align:top"><p>No dose adjustment.</p></td></tr><tr><td style="vertical-align:top"><p>45-59</p></td><td style="vertical-align:top"><p>Maximum daily dose is 2000 mg.</p><p>The starting dose is at most half of the maximum dose.</p></td><td rowspan="3" style="vertical-align:top"><p>Maximal daily dose is 50 mg.</p></td></tr><tr><td style="vertical-align:top"><p>30-44</p></td><td style="vertical-align:top"><p>Maximum daily dose is 1000 mg.</p><p>The starting dose is at most half of the maximum dose.</p></td></tr><tr><td style="vertical-align:top"><p>&lt;30</p></td><td style="vertical-align:top"><p>Metformin is contraindicated.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>JALRA M should not be used in patients with hepatic impairment, including those with pre-treatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 3 times the upper limit of normal (ULN) (see sections 4.3, 4.4 and 4.8).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>JALRA M is not recommended for use in children and adolescents (&lt; 18 years). The safety and efficacyof JALRA M in children and adolescents (&lt; 18 years) have not been established. No data are available.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Oral use.</p><p>Taking JALRA M with or just after food may reduce gastrointestinal symptoms associated withmetformin (see also section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Hypersensitivity to the active substances or to any of the excipients listed in section 6.1
	Any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis)
	Diabetic pre-coma
	Severe renal failure (GFR < 30 ml/min) (see section 4.4)
 
	Acute conditions with the potential to alter renal function, such as:
-	dehydration,
-	severe infection,
-	shock,
-	intravascular administration of iodinated contrast agents (see section 4.4).
	Acute or chronic disease which may cause tissue hypoxia, such as:
-	cardiac or respiratory failure,
-	recent myocardial infarction,
-	shock.
	Hepatic impairment (see sections 4.2, 4.4 and 4.8)
	Acute alcohol intoxication, alcoholism
	Breast-feeding (see section 4.6)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>&nbsp;</p><p>&nbsp;</p><p>JALRA M is not a substitute for insulin in insulin-requiring patients and should not be used in patients with type 1 diabetes.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Lactic acidosis</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Lactic acidosis, a very rare but serious metabolic complication, most often occurs at acute worsening of renal function, or cardiorespiratory illness or sepsis. Metformin accumulation occurs at acute worsening of renal function and increases the risk of lactic acidosis.</p><p>&nbsp;</p><p>&nbsp;</p><p>In case of dehydration (severe diarrhoea or vomiting, fever or reduced fluid intake), metformin should be temporarily discontinued and contact with a health care professional is recommended.</p><p>&nbsp;</p><p>&nbsp;</p><p>Medicinal products that can acutely impair renal function (such as antihypertensives, diuretics and NSAIDs) should be initiated with caution in metformin-treated patients. Other risk factors for lactic acidosis are excessive alcohol intake, hepatic insufficiency, inadequately controlled diabetes, ketosis, prolonged fasting and any conditions associated with hypoxia, as well as concomitant use of medicinal products that may cause lactic acidosis (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p>Patients and/or care-givers should be informed of the risk of lactic acidosis. Lactic acidosis is characterised by acidotic dyspnoea, abdominal pain, muscle cramps, asthenia and hypothermia followed by coma. In case of suspected symptoms, the patient should stop taking metformin and seek immediate medical attention. Diagnostic laboratory findings are decreased blood pH (&lt; 7.35), increased plasma lactate levels (&gt; 5 mmol/l) and an increased anion gap and lactate/pyruvate ratio.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Administration of iodinated contrast agents</u></em></p><p>Intravascular administration of iodinated contrast agents may lead to contrast-induced nephropathy, resulting in metformin accumulation and increased risk of lactic acidosis. Metformin should be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable (see sections 4.2 and 4.5).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Renal function</u></p><p>&nbsp;</p><p>&nbsp;</p><p>GFR should be assessed before treatment initiation and regularly thereafter (see section 4.2). Metformin is contraindicated in patients with GFR &lt; 30 ml/min and should be temporarily discontinued in the presence of conditions that alter renal function (see section 4.3).</p><p>&nbsp;</p><p>&nbsp;</p><p>Concomitant medicinal products that may affect renal function, result in significant haemodynamic change, or inhibit renal transport and increase metformin systemic exposure, should be used with caution (see section 4.5).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Patients with hepatic impairment, including those with pre-treatment ALT or AST &gt; 3x ULN, should not be treated with JALRA M (see sections 4.2, 4.3 and 4.8).</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Liver enzyme monitoring</u></em></p><p>Rare cases of hepatic dysfunction (including hepatitis) have been reported with vildagliptin. In these cases, the patients were generally asymptomatic without clinical sequelae and liver function tests (LFTs) returned to normal after discontinuation of treatment. LFTs should be performed prior to the initiation of treatment with JALRA M in order to know the patient&rsquo;s baseline value. Liver function should be monitored during treatment with JALRA M at three-month intervals during the first year and periodicallythereafter.</p><p>Patients who develop increased transaminase levels should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent LFTs until the abnormality(ies) return(s) to normal. Should an increase in AST or in ALT of 3x ULN or greater persist, withdrawal of JALRA M therapy is recommended. Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue JALRA M.</p><p>&nbsp;</p><p>Following withdrawal of treatment with JALRA M and LFT normalisation, treatment with JALRA Mshould not be re-initiated.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Skin disorders</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Skin lesions, including blistering and ulceration have been reported with vildagliptin in extremities of monkeys in non-clinical toxicology studies (see section 5.3). Although skin lesions were not observed at an increased incidence in clinical trials, there was limited experience in patients with diabetic skin complications. Furthermore, there have been post-marketing reports of bullous and exfoliative skin lesions. Therefore, in keeping with routine care of the diabetic patient, monitoring for skin disorders, such as blistering or ulceration, is recommended.</p><p>&nbsp;</p><p><u>Acute pancreatitis</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Use of vildagliptin has been associated with a risk of developing acute pancreatitis. Patients should be informed of the characteristic symptom of acute pancreatitis.</p><p>&nbsp;</p><p>&nbsp;</p><p>If pancreatitis is suspected, vildagliptin should be discontinued; if acute pancreatitis is confirmed, vildagliptin should not be restarted. Caution should be exercised in patients with a history of acute pancreatitis.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Hypoglycaemia</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Sulphonylureas are known to cause hypoglycaemia. Patients receiving vildagliptin in combination with a sulphonylurea may be at risk for hypoglycaemia. Therefore, a lower dose of sulphonylurea may be considered to reduce the risk of hypoglycaemia.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Surgery</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Metformin must be discontinued at the time of surgery under general, spinal or epidural anaesthesia. Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition and provided that renal function has been re-evaluated and found to be stable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been no formal interaction studies for JALRA M. The following statements reflect theinformation available on the individual active substances.</p><p>&nbsp;</p><p><u>Vildagliptin</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Vildagliptin has a low potential for interactions with co-administered medicinal products. Since vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and does not inhibit or induce CYP 450 enzymes, it is not likely to interact with active substances that are substrates, inhibitors or inducers of these enzymes.</p><p>&nbsp;</p><p>&nbsp;</p><p>Results from clinical trials conducted with the oral antidiabetics pioglitazone, metformin and glyburide in combination with vildagliptin have shown no clinically relevant pharmacokinetic interactions in the target population.</p><p>&nbsp;</p><p>&nbsp;</p><p>Drug-drug interaction studies with digoxin (P-glycoprotein substrate) and warfarin (CYP2C9 substrate) in healthy subjects have shown no clinically relevant pharmacokinetic interactions after co-administration with vildagliptin.</p><p>&nbsp;</p><p>Drug-drug interaction studies in healthy subjects were conducted with amlodipine, ramipril, valsartan and simvastatin. In these studies, no clinically relevant pharmacokinetic interactions were observed after co- administration with vildagliptin. However, this has not been established in the target population.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Combination with ACE inhibitors</u></em></p><p>There may be an increased risk of angioedema in patients concomitantly taking ACE inhibitors.(see section 4.8).</p><p>&nbsp;</p><p>&nbsp;</p><p>As with other oral antidiabetic medicinal products the hypoglycaemic effect of vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Metformin</u></p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Combinations</u></em><em><u> </u></em><em><u>not recommended</u></em><em> </em><em>Alcohol</em></p><p>Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in cases of fasting, malnutrition or hepatic impairment.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Iodinated contrast agents</em></p><p>Metformin must be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><em><u>Combinations requiring precautions for use</u></em></p><p>Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics. When starting or using such products in combination with metformin, close monitoring of renal function is necessary.</p><p>&nbsp;</p><p>Glucocorticoids, beta-2-agonists, and diuretics have intrinsic hyperglycaemic activity. The patient should be informed and more frequent blood glucose monitoring performed, especially at the beginning of treatment. If necessary, the dosage of JALRA M may need to be adjusted during concomitant therapy and on its discontinuation.</p><p>&nbsp;</p><p>&nbsp;</p><p>Angiotensin converting enzyme (ACE) inhibitors may decrease the blood glucose levels. If necessary, the dosage of the antihyperglycaemic medicinal product should be adjusted during therapy with the other medicinal product and on its discontinuation.</p><p>&nbsp;</p><p>&nbsp;</p><p>Concomitant use of medicinal products that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g. organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir and cimetidine) could increase systemic exposure to metformin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>&nbsp;</p><p>There are no adequate data from the use of JALRA M in pregnant women. For vildagliptin studies in animals have shown reproductive toxicity at high doses. For metformin, studies in animals have not shown reproductive toxicity. Studies in animals performed with vildagliptin and metformin have not shown evidence of teratogenicity, but foetotoxic effects at maternotoxic doses (see section 5.3). The potential risk for humans is unknown. JALRA M should not be used during pregnancy.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Studies in animals have shown excretion of both metformin and vildagliptin in milk. It is unknown whether vildagliptin is excreted in human milk, but metformin is excreted in human milk in low amounts. Due to both the potential risk of neonate hypoglycaemia related to metformin and the lack of human data with vildagliptin, JALRA M should not be used during breast-feeding (see section 4.3).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>&nbsp;</p><p>No studies on the effect on human fertility have been conducted for JALRA M (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Patients who may experience dizziness as an adverse reaction should avoid driving vehicles or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Safety data were obtained from a total of 6 197 patients exposed to vildagliptin/metformin in randomised placebo-controlled trials. Of these patients, 3 698 patients received vildagliptin/metformin and</p><p>2 499 patients received placebo/metformin.</p><p>&nbsp;</p><p>&nbsp;</p><p>There have been no therapeutic clinical trials conducted with JALRA M. However, bioequivalence ofJALRA M with co-administered vildagliptin and metformin has been demonstrated (see section 5.2).</p><p>&nbsp;</p><p>&nbsp;</p><p>The majority of adverse reactions were mild and transient, not requiring treatment discontinuations. No association was found between adverse reactions and age, ethnicity, duration of exposure or daily dose. Vildagliptin use is associated with the risk of development of pancreatitis. Lactic acidosis has been reported following the use of metformin, especially in patients with underlying renal impairment (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Adverse reactions reported in patients who received vildagliptin in double-blind clinical trials as monotherapy and add-on therapies are listed below by system organ class and absolute frequency. Frequencies are defined as very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1 000 to</p><p>&lt;1/100); rare (&ge;1/10 000 to &lt;1/1 000); very rare (&lt;1/10 000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions reported in patients who received vildagliptin and metformin (as mono-components or as fixed dose combination), or in combination with other anti-</p><p>&nbsp;</p><p><strong>diabetic treatments, in clinical trials and in post-marketing experience</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class - adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism</strong><strong> </strong><strong>and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypoglycaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Loss of appetite</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Decrease of vitamin B12 absorption and lactic acidosis</p></td><td style="vertical-align:top"><p>Very rare*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Metallic taste</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastro-oesophageal reflux disease</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Flatulence</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain including upper</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hepatitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hyperhidrosis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pruritis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dermatitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Erythema</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Exfoliative and bullous skin lesions, including bullous pemphigoid</p></td><td style="vertical-align:top"><p>Not known&dagger;</p></td></tr><tr><td style="vertical-align:top"><p>Cutaneous vasculitis</p></td><td style="vertical-align:top"><p>Not known&dagger;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal</strong><strong> </strong><strong>and</strong><strong> </strong><strong>connective</strong><strong> </strong><strong>tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Arthalgia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Oedema peripheral</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Abnormal liver function tests</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>*&nbsp;&nbsp; &nbsp;Adverse reactions reported in patients who received metformin as monotherapy and that were not observed in patients who received vildalgiptin+metformin fixed dose combination. Refer to summary of product characteristics for metformin for additional information.</p><p>&dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on post-marketing experience.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Vildagliptin</u></em></p><p><em>Hepatic impairment</em></p><p><!--[if gte vml 1]><v:rect
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:253.7pt;margin-top:44.15pt;width:2.75pt;height:.7pt;z-index:-16296448;
 mso-position-horizontal-relative:page' fillcolor="black" stroked="f">
 <w:wrap anchorx="page"/>
</v:rect><![endif]--><img width="4" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />Rare cases of hepatic dysfunction (including hepatitis) have been reported with vildagliptin. In these cases, the patients were generally asymptomatic without clinical sequelae and liver function returned to normal after discontinuation of treatment. In data from controlled monotherapy and add-on therapy trials of up to 24 weeks in duration, the incidence of ALT or AST elevations &ge; 3x ULN (classified as present on at least 2 consecutive measurements or at the final on-treatment visit) was 0.2%, 0.3% and 0.2% for vildagliptin 50 mg once daily, vildagliptin 50 mg twice daily and all comparators, respectively. These</p><p>&nbsp;</p><p>elevations in transaminases were generally asymptomatic, non-progressive in nature and not associated with cholestasis or jaundice.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Angioedema</em></p><p>Rare cases of angioedema have been reported on vildagliptin at a similar rate to controls. A greater proportion of cases were reported when vildagliptin was administered in combination with an ACE inhibitor. The majority of events were mild in severity and resolved with ongoing vildagliptin treatment.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Hypoglycaemia</em></p><p>Hypoglycaemia was uncommon when vildagliptin (0.4%) was used as monotherapy in comparative controlled monotherapy studies with an active comparator or placebo (0.2%). No severe or serious events of hypoglycaemia were reported. When used as add-on to metformin, hypoglycaemia occurred in 1% of vildagliptin-treated patients and in 0.4% of placebo-treated patients. When pioglitazone was added, hypoglycaemia occurred in 0.6% of vildagliptin-treated patients and in 1.9% of placebo-treated patients. When sulphonylurea was added, hypoglycaemia occurred in 1.2% of vildagliptin treated patients and in 0.6% of placebo-treated patients. When sulphonylurea and metformin were added, hypoglycaemia occurred in 5.1% of vildagliptin-treated patients and in 1.9% of placebo-treated patients. In patients taking vildagliptin in combination with insulin, the incidence of hypoglycaemia was 14% for vildagliptin and 16% for placebo.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Metformin</u></em></p><p><em>Decrease of vitamin B</em><em>12 </em><em>absorption</em></p><p>A decrease in vitamin B12 absorption with decrease in serum levels has been observed very rarely in patients who have been treated with metformin over a long period. Consideration of such aetiology is recommended if a patient presents with megaloblastic anaemia.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Liver function</em></p><p>Isolated cases of liver function test abnormalities or hepatitis resolving upon metformin discontinuation have been reported.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Gastrointestinal disorders</em></p><p>Gastrointestinal adverse reactions occur most frequently during initiation of therapy and resolve spontaneously in most cases. To prevent them, it is recommended that metformin be taken in 2 daily doses during or after meals. A slow increase in the dose may also improve gastrointestinal tolerability.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&nbsp;</p><p>Saudi Arabia:</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
  margin-left:105.6pt;margin-top:11.95pt;width:390.2pt;height:70.15pt;
  z-index:-15728128;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.1pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.15pt;margin-bottom:.0001pt'>-The<span style='letter-spacing:
     -.2pt'> </span>national<span style='letter-spacing:-.1pt'> </span>pharmacovigilance<span
     style='letter-spacing:-.2pt'> </span>center<span style='letter-spacing:
     -.15pt'> </span>(NPC):<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:5.9pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.15pt;margin-bottom:.0001pt'>-SFDA<span style='letter-spacing:
     -.65pt'> </span>call<span style='letter-spacing:-.2pt'> </span>center:<span
     style='letter-spacing:-.15pt'> </span>19999<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:5.9pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.15pt;margin-bottom:.0001pt'>-E-mail:<span
     style='letter-spacing:-.5pt'> </span><a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:#006FC0;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:5.9pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.15pt;margin-bottom:.0001pt'>-Website:<span
     style='letter-spacing:-.6pt'> </span><a href="http://ade.sfda.gov.sa/"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>http://ade.sfda.gov.sa</span></a><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="526" height="99" alt="Text Box: -The national pharmacovigilance center (NPC):
-SFDA call center: 19999
-E-mail: npc.drug@sfda.gov.sa
-Website: http://ade.sfda.gov.sa
" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Other GCC states and other countries:</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1028" type="#_x0000_t202" style='position:absolute;margin-left:105.6pt;
  margin-top:12.05pt;width:390.2pt;height:17.9pt;z-index:-15727616;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.1pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.15pt;margin-bottom:.0001pt'>-Please<span
     style='letter-spacing:-.2pt'> </span>contact<span style='letter-spacing:
     -.2pt'> </span>the<span style='letter-spacing:-.05pt'> </span>relevant<span
     style='letter-spacing:-.2pt'> </span>competent<span style='letter-spacing:
     -.1pt'> </span>authority<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="526" height="30" alt="Text Box: -Please contact the relevant competent authority" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data are available with regard to overdose of JALRA M.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Vildagliptin</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Information regarding overdose with vildagliptin is limited.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Symptoms</u></em></p><p>Information on the likely symptoms of overdose with vildagliptin was taken from a rising dose tolerability study in healthy subjects given vildagliptin for 10 days. At 400 mg, there were three cases of muscle pain, and individual cases of mild and transient paraesthesia, fever, oedema and a transient increase in lipase levels. At 600 mg, one subject experienced oedema of the feet and hands, and increases in creatine</p><p>&nbsp;</p><p>phosphokinase (CPK), AST, C-reactive protein (CRP) and myoglobin levels. Three other subjects experienced oedema of the feet, with paraesthesia in two cases. All symptoms and laboratory abnormalities resolved without treatment after discontinuation of the study medicinal product.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Metformin</u></p><p>&nbsp;</p><p>&nbsp;</p><p>A large overdose of metformin (or co-existing risk of lactic acidosis) may lead to lactic acidosis, which is a medical emergency and must be treated in hospital.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Management</u></em></p><p>The most effective method of removing metformin is haemodialysis. However, vildagliptin cannot be removed by haemodialysis, although the major hydrolysis metabolite (LAY 151) can. Supportive management is recommended.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs, ATC code: A10BD08</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>&nbsp;</p><p>JALRA M combines two antihyperglycaemic agents with complimentary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: vildagliptin, a member of the islet enhancer class, and metformin hydrochloride, a member of the biguanide class.</p><p>&nbsp;</p><p>&nbsp;</p><p>Vildagliptin, a member of the islet enhancer class, is a potent and selective dipeptidyl-peptidase-4 (DPP- 4) inhibitor. Metformin acts primarily by decreasing endogenous hepatic glucose production.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Vildagliptin</u></em></p><p>Vildagliptin acts primarily by inhibiting DPP-4, the enzyme responsible for the degradation of the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).</p><p>&nbsp;</p><p>&nbsp;</p><p>The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 and GIP.</p><p>&nbsp;</p><p>&nbsp;</p><p>By increasing the endogenous levels of these incretin hormones, vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion. Treatment with vildagliptin 50-100 mg daily in patients with type 2 diabetes significantly improved markers of beta cell function including HOMA-b (Homeostasis Model Assessment&ndash;b), proinsulin to insulin ratio and measures of beta cell responsiveness from the frequently-sampled meal tolerance test. In non-diabetic (normal glycaemic) individuals, vildagliptin does not stimulate insulin secretion or reduce glucose levels.</p><p>&nbsp;</p><p>&nbsp;</p><p>By increasing endogenous GLP-1 levels, vildagliptin also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion.</p><p>&nbsp;</p><p>&nbsp;</p><p>The enhanced increase in the insulin/glucagon ratio during hyperglycaemia due to increased incretin hormone levels results in a decrease in fasting and postprandial hepatic glucose production, leading to reduced glycaemia.</p><p>&nbsp;</p><p>&nbsp;</p><p>The known effect of increased GLP-1 levels delaying gastric emptying is not observed with vildagliptin treatment.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Metformin</u></em></p><p>Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia or increased weight gain.</p><p>&nbsp;</p><p>&nbsp;</p><p>Metformin may exert its glucose-lowering effect via three mechanisms:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by reduction of hepatic glucose production through inhibition of gluconeogenesis and glycogenolysis;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in muscle, by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by delaying intestinal glucose absorption.</p><p>Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase and increases the transport capacity of specific types of membrane glucose transporters (GLUT-1 and GLUT-4).</p><p>&nbsp;</p><p>&nbsp;</p><p>In humans, independently of its action on glycaemia, metformin has favourable effects on lipid metabolism. This has been shown at therapeutic doses in controlled, medium-term or long-term clinical studies: metformin reduces serum levels of total cholesterol, LDL cholesterol and triglycerides.</p><p>&nbsp;</p><p>&nbsp;</p><p>The prospective randomised UKPDS (UK Prospective Diabetes Study) study has established the long- term benefit of intensive blood glucose control in type 2 diabetes. Analysis of the results for overweight patients treated with metformin after failure of diet alone showed:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a significant reduction in the absolute risk of any diabetes-related complication in the metformin group (29.8 events/1 000 patient-years) versus diet alone (43.3 events/1 000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups</p><p>(40.1 events/1 000 patient-years), p=0.0034;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a significant reduction in the absolute risk of diabetes-related mortality: metformin</p><p>7.5 events/1 000 patient-years, diet alone 12.7 events/1 000 patient-years, p=0.017;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a significant reduction in the absolute risk of overall mortality: metformin 13.5 events/1 000 patient- years versus diet alone 20.6 events/1 000 patient-years (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/1 000 patient-years (p=0.021);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a significant reduction in the absolute risk of myocardial infarction: metformin</p><p>11 events/1 000 patient-years, diet alone 18 events/1 000 patient-years (p=0.01).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Vildagliptin added to patients whose glycaemic control was not satisfactory despite treatment with metformin monotherapy resulted after 6-month treatment in additional statistically significant mean reductions in HbA1c compared to placebo (between group differences of -0.7% to -1.1% for vildagliptin</p><p>50 mg and 100 mg, respectively). The proportion of patients who achieved a decrease in HbA1c of &ge; 0.7% from baseline was statistically significantly higher in both vildagliptin plus metformin groups (46% and 60%, respectively) versus the metformin plus placebo group (20%).</p><p>&nbsp;</p><p>&nbsp;</p><p>In a 24-week trial, vildagliptin (50 mg twice daily) was compared to pioglitazone (30 mg once daily) in patients inadequately controlled with metformin (mean daily dose: 2020 mg). Mean reductions from baseline HbA1c of 8.4% were -0.9% with vildagliptin added to metformin and -1.0% with pioglitazone added to metformin. A mean weight gain of +1.9 kg was observed in patients receiving pioglitazone added to metformin compared to +0.3 kg in those receiving vildagliptin added to metformin.</p><p>&nbsp;</p><p><strong>In </strong>a clinical <strong>trial of 2 years&rsquo; duration, vildagliptin (</strong>50 mg twice daily<strong>) was compared to glimepiride (up to 6 mg/day </strong>&ndash; mean dose at 2 years: 4.6 mg<strong>) in patients treated with metformin </strong>(mean daily dose: 1894 mg)<strong>. After 1 year mean reductions in HbA</strong><strong>1c</strong></p><p>&nbsp;</p><p>were -0.4% with vildagliptin added to metformin and -0.5% with glimepiride added to metformin, from a mean baseline HbA1c of 7.3%. Body weight change with vildagliptin was -0.2 kg vs +1.6 kg with glimepiride. The incidence of hypoglycaemia was significantly lower in the vildagliptin group (1.7%) than in the glimepiride group (16.2%). At study endpoint (2 years), the HbA1c was similar to baseline values in both treatment groups and the body weight changes and hypoglycaemia differences were maintained.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>In a 52-week trial, vildagliptin (50 mg twice daily) was compared to gliclazide (</strong>mean daily dose: 229.5 mg<strong>) in patients inadequately controlled with metformin </strong>(metformin dose at baseline 1928 mg/day)<strong>. After 1 year, mean reductions in HbA</strong><strong>1c were -0.81% with vildagliptin added to metformin (mean baseline HbA</strong><strong>1c 8.4%) and -0.85% with gliclazide added to metformin (mean baseline HbA</strong><strong>1c 8.5%); statistical non-inferiority was achieved </strong>(95% CI -0.11 &ndash; 0.20)<strong>. Body weight change with vildagliptin was +0.1 kg compared to a weight gain of +1.4 kg with gliclazide.</strong></p><p><strong>&nbsp;</strong></p><p>In a 24-week trial the efficacy of the fixed dose combination of vildagliptin and metformin (gradually titrated to a dose of 50 mg/500 mg twice daily or</p><p><strong>50 mg/1000 mg twice daily) as initial therapy in drug-na&iuml;ve patients was evaluated. Vildagliptin/metformin 50 mg/1000 mg twice daily reduced HbA</strong><strong>1c </strong><strong>by -1.82% ,vildagliptin/metformin 50 mg/500 mg twice daily by -1.61%, </strong>metformin</p><p>1000 mg twice daily by -1.36% and vildagliptin 50 mg twice daily by -1.09% <strong>from a mean baseline HbA</strong><strong>1c </strong><strong>of 8.6%. The decrease in HbA</strong><strong>1c </strong><strong>observed in patients with a baseline &ge;10.0% </strong><strong>was greater.</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>A 24-week randomised, double-blind, placebo-controlled trial was conducted in 318 patients to evaluate the efficacy and safety of vildagliptin (50 mg twice daily) in combination with metformin (&ge;1500 mg daily) and glimepiride (&ge;4 mg daily).</p><p><strong>Vildagliptin in combination with metformin and glimepiride significantly decreased HbA</strong><strong>1c </strong><strong>compared with placebo. The placebo-adjusted mean reduction from a mean baseline HbA</strong><strong>1c </strong><strong>of 8.8% was -0.76%.</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>A five-year multi-centre, randomised, double-blind study (VERIFY) was conducted in patients with type 2 diabetes to evaluate the effect of an early combination therapy with vildagliptin and metformin (N</p><p>= 998) against standard-of-care initial metformin monotherapy followed by combination with vildagliptin (sequential treatment group) (N = 1 003) in newly diagnosed patients with type 2 diabetes. The combination regimen of vildagliptin 50 mg twice daily plus metformin resulted in a statistically and clinically significant relative reduction in hazard for &ldquo;time to confirmed initial treatment failure&rdquo; (HbA1c value &ge;7%) vs metformin monotherapy in treatment-na&iuml;ve patients with type 2 diabetes over the 5-year study duration (HR [95%CI]: 0.51 [0.45, 0.58]; p&lt;0.001). The incidence of initial treatment failure (HbA1c value &ge;7%) was 429 (43.6%) patients in the combination treatment group and</p><p>614 (62.1%) patients in the sequential treatment group.</p><p>&nbsp;</p><p>A 24-week randomised, double-blind, placebo-controlled trial was conducted in 449 patients to evaluate the efficacy and safety of vildagliptin (50 mg twice daily) in combination with a stable dose of basal or premixed insulin (mean daily dose 41 units), with concomitant use of metformin (N=276) or without concomitant metformin (N=173). Vildagliptin in combination with insulin significantly decreased HbA1c compared with placebo. In the overall population, the placebo-adjusted mean reduction from a mean baseline HbA1c 8.8% was -0.72%. In the subgroups treated with insulin with or without concomitant metformin the placebo-adjusted mean reduction in HbA1c was -0.63% and -0.84%, respectively. The incidence of hypoglycaemia in the overall population was 8.4% and 7.2% in the vildagliptin and placebo groups, respectively. Patients receiving vildagliptin experienced no weight gain (+0.2 kg) while those receiving placebo experienced weight reduction (-0.7 kg).</p><p>&nbsp;</p><p>&nbsp;</p><p>In another 24-week study in patients with more advanced type 2 diabetes not adequately controlled on insulin (short and longer acting, average insulin dose 80 IU/day), the mean reduction in HbA1c when vildagliptin (50 mg twice daily) was added to insulin was statistically significantly greater than with placebo plus insulin (0.5% vs. 0.2%). The incidence of hypoglycaemia was lower in the vildagliptin group than in the placebo group (22.9% vs. 29.6%).</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Cardiovascular risk</p><p>A meta-analysis of independently and prospectively adjudicated cardiovascular events from 37 phase III and IV monotherapy and combination therapy clinical studies of up to more than 2 years duration (mean exposure 50 weeks for vildagliptin and 49 weeks for comparators) was performed and showed that vildagliptin treatment was not associated with an increase in cardiovascular risk versus comparators. The composite endpoint of adjudicated major adverse cardiovascular events (MACE) including acute myocardial infarction, stroke or cardiovascular death was similar for vildagliptin versus combined active and placebo comparators [Mantel&ndash;Haenszel risk ratio (M-H RR) 0.82 (95% CI 0.61-1.11)]. A MACE occurred in 83 out of 9 599 (0.86%) vildagliptin-treated patients and in 85 out of 7 102 (1.20%) comparator-treated patients. Assessment of each individual MACE component showed no increased risk (similar M-H RR). Confirmed heart failure (HF) events defined as HF requiring hospitalisation or new onset of HF were reported in 41 (0.43%) vildagliptin-treated patients and 32 (0.45%) comparator-treated patients with M-H RR 1.08 (95% CI 0.68-1.70).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with vildagliptin in combination with metformin in all subsets of the paediatric population with type 2 diabetes mellitus (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>JALRA M</u></p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Absorption</u></em></p><p>Bioequivalence has been demonstrated between JALRA M at three dose strengths (50 mg/500 mg, 50 mg/850 mg and 50 mg/1000 mg) versus free combination of vildagliptin and metformin hydrochloride tablets at the corresponding doses.</p><p>&nbsp;</p><p>&nbsp;</p><p>Food does not affect the extent and rate of absorption of vildagliptin from JALRA M. The rate and extentof absorption of metformin from JALRA M 50 mg/1000 mg were decreased when given with food as reflected by the decrease in Cmax by 26%, AUC by 7% and delayed Tmax (2.0 to 4.0 h).</p><p>&nbsp;</p><p>&nbsp;</p><p>The following statements reflect the pharmacokinetic properties of the individual active substances of JALRA M.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Vildagliptin</u></p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Absorption</u></em></p><p>Following oral administration in the fasting state, vildagliptin is rapidly absorbed with peak plasma concentrations observed at 1.7 hours. Food slightly delays the time to peak plasma concentration to</p><p>2.5 hours, but does not alter the overall exposure (AUC). Administration of vildagliptin with food resulted in a decreased Cmax (19%) compared to dosing in the fasting state. However, the magnitude of change is not clinically significant, so that vildagliptin can be given with or without food. The absolute bioavailability is 85%.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Distribution</u></em></p><p>The plasma protein binding of vildagliptin is low (9.3%) and vildagliptin distributes equally between plasma and red blood cells. The mean volume of distribution of vildagliptin at steady-state after intravenous administration (Vss) is 71 litres, suggesting extravascular distribution.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Biotransformation</u></em></p><p>Metabolism is the major elimination pathway for vildagliptin in humans, accounting for 69% of the dose. The major metabolite (LAY 151) is pharmacologically inactive and is the hydrolysis product of the cyano moiety, accounting for 57% of the dose, followed by the amide hydrolysis product (4% of dose). DPP-4 contributes partially to the hydrolysis of vildagliptin based on an <em>in vivo </em>study using DPP-4 deficient rats. Vildagliptin is not metabolised by CYP 450 enzymes to any quantifiable extent, and accordingly the metabolic clearance of vildagliptin is not anticipated to be affected by co-medications that are CYP 450 inhibitors and/or inducers. <em>In vitro </em>studies demonstrated that vildagliptin does not inhibit/induce CYP 450</p><p>&nbsp;</p><p>enzymes. Therefore, vildagliptin is not likely to affect metabolic clearance of co-medications metabolised by CYP 1A2, CYP 2C8, CYP 2C9, CYP 2C19, CYP 2D6, CYP 2E1 or CYP 3A4/5.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Elimination</u></em></p><p>Following oral administration of [14C] vildagliptin, approximately 85% of the dose was excreted into the urine and 15% of the dose was recovered in the faeces. Renal excretion of the unchanged vildagliptin accounted for 23% of the dose after oral administration. After intravenous administration to healthy subjects, the total plasma and renal clearances of vildagliptin are 41 and 13 l/h, respectively. The mean elimination half-life after intravenous administration is approximately 2 hours. The elimination half-life after oral administration is approximately 3 hours.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Linearity/non-linearity</u></em></p><p>The Cmax for vildagliptin and the area under the plasma concentrations versus time curves (AUC) increased in an approximately dose proportional manner over the therapeutic dose range.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Characteristics in patients</u></em></p><p>Gender: No clinically relevant differences in the pharmacokinetics of vildagliptin were observed between male and female healthy subjects within a wide range of age and body mass index (BMI). DPP-4 inhibition by vildagliptin is not affected by gender.</p><p>&nbsp;</p><p>&nbsp;</p><p>Age: In healthy elderly subjects (&ge; 70 years), the overall exposure of vildagliptin (100 mg once daily) was increased by 32%, with an 18% increase in peak plasma concentration as compared to young healthy subjects (18-40 years). These changes are not considered to be clinically relevant, however. DPP-4 inhibition by vildagliptin is not affected by age.</p><p>&nbsp;</p><p>&nbsp;</p><p>Hepatic impairment: In subjects with mild, moderate or severe hepatic impairment (Child-Pugh A-C) there were no clinically significant changes (maximum ~30%) in exposure to vildagliptin.</p><p>&nbsp;</p><p>&nbsp;</p><p>Renal impairment: In subjects with mild, moderate, or severe renal impairment, systemic exposure to vildagliptin was increased (Cmax 8-66%; AUC 32-134%) and total body clearance was reduced compared to subjects with normal renal function.</p><p>&nbsp;</p><p>&nbsp;</p><p>Ethnic group: Limited data suggest that race does not have any major influence on vildagliptin pharmacokinetics.</p><p>&nbsp;</p><p><u>Metformin</u></p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Absorption</u></em></p><p>After an oral dose of metformin, the maximum plasma concentration (Cmax) is achieved after about 2.5 h. Absolute bioavailability of a 500 mg metformin tablet is approximately 50-60% in healthy subjects. After an oral dose, the non-absorbed fraction recovered in faeces was 20-30%.</p><p>&nbsp;</p><p>&nbsp;</p><p>After oral administration, metformin absorption is saturable and incomplete. It is assumed that the pharmacokinetics of metformin absorption are non-linear. At the usual metformin doses and dosing schedules, steady state plasma concentrations are reached within 24-48 h and are generally less than 1 &micro;g/ml. In controlled clinical trials, maximum metformin plasma levels (Cmax) did not exceed 4 &micro;g/ml, even at maximum doses.</p><p>&nbsp;</p><p>&nbsp;</p><p>Food slightly delays and decreases the extent of the absorption of metformin. Following administration of a dose of 850 mg, the plasma peak concentration was 40% lower, AUC was decreased by 25% and time to peak plasma concentration was prolonged by 35 minutes. The clinical relevance of this decrease is unknown.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Distribution</u></em></p><p>Plasma protein binding is negligible. Metformin partitions into erythrocytes. The mean volume of distribution (Vd) ranged between 63-276 litres.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Biotransformation</u></em></p><p>Metformin is excreted unchanged in the urine. No metabolites have been identified in humans.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Elimination</u></em></p><p>Metformin is eliminated by renal excretion. Renal clearance of metformin is &gt; 400 ml/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion. Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 h. When renal function is impaired, renal clearance is decreased in proportion to that of creatinine and thus the elimination half-life is prolonged, leading to increased levels of metformin in plasma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal studies of up to 13-week duration have been conducted with the combined substances in JALRA</p><p>M. No new toxicities associated with the combination were identified. The following data are findings from studies performed with vildagliptin or metformin individually.</p><p>&nbsp;</p><p><u>Vildagliptin</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Intra-cardiac impulse conduction delays were observed in dogs with a no-effect dose of 15 mg/kg (7-fold human exposure based on Cmax).</p><p>&nbsp;</p><p>&nbsp;</p><p>Accumulation of foamy alveolar macrophages in the lung was observed in rats and mice. The no-effect dose in rats was 25 mg/kg (5-fold human exposure based on AUC) and in mice 750 mg/kg (142-fold human exposure).</p><p>&nbsp;</p><p>&nbsp;</p><p>Gastrointestinal symptoms, particularly soft faeces, mucoid faeces, diarrhoea and, at higher doses, faecal blood were observed in dogs. A no-effect level was not established.</p><p>&nbsp;</p><p>&nbsp;</p><p>Vildagliptin was not mutagenic in conventional <em>in vitro </em>and <em>in vivo </em>tests for genotoxicity.</p><p>&nbsp;</p><p>&nbsp;</p><p>A fertility and early embryonic development study in rats revealed no evidence of impaired fertility, reproductive performance or early embryonic development due to vildagliptin. Embryofoetal toxicity was evaluated in rats and rabbits. An increased incidence of wavy ribs was observed in rats in association with reduced maternal body weight parameters, with a no-effect dose of 75 mg/kg (10-fold human exposure). In rabbits, decreased foetal weight and skeletal variations indicative of developmental delays were noted only in the presence of severe maternal toxicity, with a no-effect dose of 50 mg/kg (9-fold human exposure). A pre- and postnatal development study was performed in rats. Findings were only observed in association with maternal toxicity at &ge; 150 mg/kg and included a transient decrease in body weight and reduced motor activity in the F1 generation.</p><p>&nbsp;</p><p>&nbsp;</p><p>A two-year carcinogenicity study was conducted in rats at oral doses up to 900 mg/kg (approximately 200 times human exposure at the maximum recommended dose). No increases in tumour incidence attributable to vildagliptin were observed. Another two-year carcinogenicity study was conducted in mice at oral doses up to 1000 mg/kg. An increased incidence of mammary adenocarcinomas and haemangiosarcomas was observed with a no-effect dose of 500 mg/kg (59-fold human exposure) and 100 mg/kg (16-fold human exposure), respectively. The increased incidence of these tumours in mice is considered not to represent a significant risk to humans based on the lack of genotoxicity of vildagliptin and its principal metabolite, the occurrence of tumours only in one species, and the high systemic exposure ratios at which tumours were observed.</p><p>&nbsp;</p><p>&nbsp;</p><p>In a 13-week toxicology study in cynomolgus monkeys, skin lesions have been recorded at doses</p><p>&ge; 5 mg/kg/day. These were consistently located on the extremities (hands, feet, ears and tail). At</p><p>5 mg/kg/day (approximately equivalent to human AUC exposure at the 100 mg dose), only blisters were observed. They were reversible despite continued treatment and were not associated with histopathological abnormalities. Flaking skin, peeling skin, scabs and tail sores with correlating histopathological changes were noted at doses &ge; 20 mg/kg/day (approximately 3 times human AUC exposure at the 100 mg dose). Necrotic lesions of the tail were observed at &ge; 80 mg/kg/day. Skin lesions were not reversible in the monkeys treated at 160 mg/kg/day during a 4-week recovery period.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Metformin</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Non-clinical data on metformin reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Hydroxypropylcellulose Magnesium stearate</p><p>&nbsp;</p><p><u>Film-coating</u></p><p>&nbsp;</p><p>Hypromellose</p><p>Titanium dioxide (E 171) Iron oxide, yellow (E 172) Macrogol 4000</p><p>Talc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 months
 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original package (blister) in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/Aluminium (PA/Alu/PVC/Alu) blister</p><p>Available in packs containing 60 film-coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceuticals
Saudi Arabian Japanese pharmaceutical company limited Jeddah – Saudi Arabia 
Under License from Novartis Pharma AG, Switzerland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>